Proteome-wide mendelian randomization identifies FCRL3 and LY9 as potential therapeutic targets for lymphoma.

ABSTRACT:

Background

Lymphoma is a common hematologic malignancy with limited treatment options. The research objective was to ascertain plasma proteins that could be targeted for lymphoma treatment.

Methods

We conducted proteome-wide mendelian randomization (PW-MR) analyses on blood proteins from the deCODE (N = 355,559) and Fenland (N = 10,708) studies. Protein-protein interaction (PPI), sensitivity analysis and external validation were used to identify potential drug targets. We analyzed enrichment analysis, single cell sequencing, drug prediction, molecular docking, mouse genome informatics (MGI), qRT-PCR and CCK-8 assays.

Results

PW-MR analyses predicted 37 proteins associated with lymphoma. Therein, 8 proteins, including APOBEC3G, TNFAIP6, LY75, MAPK3, SERPING1, CSF2RB, F

SUBMITTER: Guo Q 

PROVIDER: S-EPMC12612436 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature